Hepatic NET metastasis embolization biomarker evaluatio

Completed

Conditions: 10014713
Neuro endocrine tumor

Registration Number: NL-OMON44840

Lead Sponsor: ederlands Kanker Instituut

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

• >= 18 years old with metastatic well differentiated neuroendocrine tumor of gastro-enteropancreatic origin who will undergo a local ablative treatment or HAE/SIRT .
• Patients have measurable disease
• WHO performance status 0-2
• Life expectancy more than 3 months
• Use of the standard embolization/RFA NET-NKI protocol

Exclusion Criteria

1. Known history of HIV seropositivity.
2. contraindication for liverembolisation, RFA/MWA or SIRT

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Effect of hepatic metastatic embolization (HAE/SIRT) on PCR score</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1) Determine whether blood PCR score correlates with metastasis burden<br /><br>2) Determine whether ablation efficacy and PCR score correlate with assessment<br /><br>of tumor anatomical burden post-ablative imaging<br /><br>3) Determine whether embolization/SIRT efficacy and PCR score correlate with<br /><br>tumor assessment anatomical burden post embolisation<br /><br>4) Correlate residual tumor burden using functional tumor imaging with PCR<br /><br>score.<br /><br>5) Evaluate stability/progression of tumor post ablation using PCR score vs.<br /><br>patient parameters and imaging.<br /><br>6) Comparison of plasma CgA measurements with the PCR score, for the same.</p><br>